Format

Send to

Choose Destination
J Nucl Med. 2019 Oct;60(10):1350-1358. doi: 10.2967/jnumed.119.228320. Epub 2019 Sep 3.

Multimodality Imaging of Prostate Cancer.

Author information

1
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and ghafoors@mskcc.org.
2
Department of Nuclear Medicine, Baden Cantonal Hospital, Baden, Switzerland.
3
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.

Abstract

Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors. In recent years, imaging has gained increasing importance in the detection, staging, posttreatment assessment, and detection of recurrence of prostate cancer. Several imaging modalities including conventional and functional methods are used in different clinical scenarios with their very own advantages and limitations. This continuing medical education article provides an overview of available imaging modalities currently in use for prostate cancer followed by a more specific section on the value of these different imaging modalities in distinct clinical scenarios, ranging from initial diagnosis to advanced, metastatic castration-resistant prostate cancer. In addition to established imaging indications, we will highlight some potential future applications of contemporary imaging modalities in prostate cancer.

KEYWORDS:

PET/MRI; PSMA; fluciclovine; multiparametric MRI; theranostics; whole-body MRI

PMID:
31481573
PMCID:
PMC6785785
[Available on 2020-04-01]
DOI:
10.2967/jnumed.119.228320

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center